Published on: May 20, 2017
by The Tribune:
Your spit may hold clues to future brain health, say scientists who have found that small molecules in saliva can help identify those at risk of developing Alzheimer’s disease.
Alzheimer’s disease, a degenerative brain disorder with no cure and few reliable diagnostic tests, is predicted to reach epidemic proportions worldwide by 2050. Scientists at the Beaumont Research Institute in the US wanted to identify valid and reliable biomarkers to diagnose the disease in its earliest stages before brain damage occurs and dementia begins. They found salivary molecules hold promise as reliable diagnostic biomarkers.
“We used metabolomics, a newer technique to study molecules involved in metabolism,” said Stewart Graham, from Beaumont Research Institute. “Our goal was to find unique patterns of molecules in the saliva of our study participants that could be used to diagnose Alzheimer’s disease in the earliest stages, when treatment is considered most effective,” said Graham. “Presently, therapies for Alzheimer’s are initiated only after a patient is diagnosed and treatments offer modest benefits,” he said.
Metabolomics is used in medicine and biology for the study of living organisms. It measures large numbers of naturally occurring small molecules, called metabolites, present in the blood, saliva and tissues. The pattern or fingerprint of metabolites in the biological sample can be used to learn about the health of the organism.
“Our team’s study demonstrates the potential for using metabolomics and saliva for the early diagnosis of Alzheimer’s disease,” said Graham. “Given the ease and convenience of collecting saliva, the development of accurate and sensitive biomarkers would be ideal for screening those at greatest risk of developing Alzheimer’s,” he said. “In fact, unlike blood or cerebrospinal fluid, saliva is one of the most noninvasive means of getting cellular samples and it’s also inexpensive,” he added.
The study participants included 29 adults in three groups – mild cognitive impairment, Alzheimer’s disease and a control group. After specimens were collected, researchers positively identified and accurately quantified 57 metabolites. Some of the observed variances in the biomarkers were significant. From their data, they were able to make predictions as to those at most risk of developing Alzheimer’s.
“Worldwide, the development of valid and reliable biomarkers for Alzheimer’s disease is considered the number one priority for most national dementia strategies,” said Graham. “It’s a necessary first step to design prevention and early-intervention research studies,” he said.
CTV's Pattie Lovett-Reid and Anne-Marie Mediwake host a virtual fundraising event featuring special guests and musical performances and Stand Ahead® for women’s brain health.
Thanks to the ongoing support of our partner Brain Canada, and The Citrine Foundation of Canada, Women’s Brain Health Initiative’s newest edition of MIND OVER MATTER has just been published. Loaded with interesting science-based articles, MIND OVER...
On December 2nd, in celebration of Women’s Brain Health Day, join thousands of others and take part in the Stand Ahead® Memory Challenge to stand up against research bias and stand ahead for women’s brain...
The material presented through the Think Tank feature on this website is in no way intended to replace professional medical care or attention by a qualified practitioner. WBHI strongly advises all questioners and viewers using this feature with health problems to consult a qualified physician, especially before starting any treatment. The materials provided on this website cannot and should not be used as a basis for diagnosis or choice of treatment. The materials are not exhaustive and cannot always respect all the most recent research in all areas of medicine.